Clik here to view.
Takeda Launches Largest Pharmaceutical Company-Sponsored Global Observational...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that its global non-interventional, observational multiple myeloma study is now enrolling...
View ArticleClik here to view.
Dr. Reddy’s Laboratories Announces the Launch of Bupropion HCl...
HYDERABAD, India & PRINCETON, N.J. Dr. Reddy’s Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Bupropion HCl extended-release tablets, USP (SR) in...
View ArticleClik here to view.
Kansas University Medical Center and Baylor Scott & White Research Institute...
SEATTLE Nativis, Inc., a clinical stage life sciences bio-electronics company developing non-invasive, medical device treatments for cancers and other serious diseases, today announced its latest...
View ArticleClik here to view.
Samsung Bioepis’ SB4 (BRENZYS™) Becomes First Etanercept Biosimilar to...
INCHEON, Korea Samsung Bioepis Co., Ltd. today announced that BRENZYS™ – a biosimilar referencing Enbrel® (etanercept), also known as SB4 – received regulatory approval in Canada for the treatment...
View ArticleClik here to view.
Takeda Supports Global Expansion of the American Cancer Society’s Relay For...
NEW YORK, & OSAKA, Japan The American Cancer Society (ACS) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced that Takeda will support the projected expansion of the ACS’s...
View ArticleClik here to view.
Ignyta to Present at 2016 Silicon Valley Bank Healthcare Capital and...
SAN DIEGO Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, announced today that Jacob Chacko, M.D., its Chief Financial Officer, will make a...
View ArticleClik here to view.
Dr. Reddy’s Expands Strategic Collaboration with Amgen in India
HYDERABAD, India Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) today announced that it has expanded its strategic collaboration with Amgen, one of the world’s leading...
View ArticleClik here to view.
Takeda Receives Positive CHMP Opinion for Conditional Approval of NINLAROTM...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE: 4502) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP)...
View ArticleClik here to view.
第2回グローバルNCDアライアンス・フォーラム、2017年12月にUAEのシャルジャで開催へ
ニューヨーク （ビジネスワイヤ） — NCDアライアンスは昨晩、第2回グローバルNCDアライアンス・フォーラムを2017年12月9～11日にアラブ首長国連邦（UAE）のシャルジャで開催すると発表しました。 このSmart News Release（スマート・ニュース・リリース）にはマルチメディアのコンテンツが含まれています。リリース全文はこちらから：...
View ArticleClik here to view.
第二届全球NCD联盟论坛将于2017年12月在阿联酋沙迦召开
纽约 (美国商业资讯) — 非传染性疾病联盟（以下简称“NCD联盟”）昨晚宣布，第二届全球NCD联盟论坛将于2017年12月9-11日在阿拉伯联合酋长国(UAE)沙迦召开。 Smart News Releases（智能新闻稿）是一个多媒体平台。在此处查看完整新闻稿： http://www.businesswire.com/news/home/20160920005830/zh-CN/...
View ArticleClik here to view.
Takeda and Affilogic enter into Research Collaboration to Develop...
OSAKA, Japan & NANTES, France Takeda Pharmaceutical Company Limited (TSE: 4502) and Affilogic today jointly announced that the companies have entered into a research collaboration to explore...
View ArticleClik here to view.
First Patient Dosed in CANbridge’s CAN-008 Phase I/II Trial in...
BEIJING CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, announced that the first patient was dosed in the Phase I/II trial...
View ArticleClik here to view.
武田薬品とアフィロジックが研究提携契約を締結し、Nanofitin®を使用して中枢神経系疾患の治療薬開発に当たる
大阪 & 仏ナント — （ビジネスワイヤ） — 武田薬品工業株式会社（TSE:...
View ArticleClik here to view.
ARIAD Announces Regulatory Approval for Iclusig® (ponatinib) in Japan
CAMBRIDGE, Mass. ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that its partner Otsuka Pharmaceutical Co., Ltd. (Otsuka) has received approval from the Japanese Pharmaceuticals and...
View ArticleClik here to view.
Agilent Technologies and Burning Rock Sign Agreement on Molecular Diagnostics
SANTA CLARA, Calif. & GUANGZHOU, China Agilent Technologies Inc. (NYSE:A) and Burning Rock today announced they have signed an agreement under which Burning Rock will develop cancer diagnostics...
View ArticleClik here to view.
Samsung Bioepis’ Marketing Authorization Application for SB3 Trastuzumab...
INCHEON, Korea Samsung Bioepis Co., Ltd. today announced that the European Medicines Agency (EMA) has accepted for review the company’s Marketing Authorization Application (MAA) for SB3, a...
View ArticleClik here to view.
Xcell Biosciences Announces Two New International Distributors and Multiple...
SAN FRANCISCO Xcell Biosciences, Inc., today announced it has signed agreements with two international distributors and made a number of international sales for its Avatar™ system. Cambridge...
View ArticleClik here to view.
IncellDxの腫瘍免疫療法向け定量的アッセイOncoTect iOに関する新研究が論文に掲載
米カリフォルニア州メンロパーク （ビジネスワイヤ） — 単一細胞を使用した精密医療技術の企業IncellDx, Inc.は本日、国際的な査読医学誌Cancer Immunology, Immunotherapyが、「非酵素的組織分散とフローサイトメトリーを使用した非小細胞肺がん（NSCLC）での腫瘍細胞および免疫細胞におけるPD-L1/PD-1発現の定量」（Quantification of...
View ArticleClik here to view.
IncellDx发表定量免疫肿瘤学检测OncoTect iO的新研究
加州门罗帕克 (美国商业资讯) — 单细胞精准医学公司IncellDx, Inc.今天宣布，国际性同行评议医学杂志《癌症免疫学与免疫治疗》(Cancer Immunology, Immunotherapy)已发表了一篇题为“采用非酶解组织解离和流式细胞计量术对非小细胞肺癌(NSCLC)肿瘤和免疫细胞上PD-L1 和PD-1表达进行定量”的稿件。公司创始人、首席执行官Bruce...
View ArticleClik here to view.
免疫细胞治疗剂‘Immuncell-LC’，延长胶质母细胞瘤的无进展生存时间1.5倍
韩国首尔 (美国商业资讯)–以“以韩国人中最新确诊的胶质母细胞瘤患者为对象，并用标准疗法和基于CIK诱导杀伤细胞的细胞免疫治疗法的第三期随机临床试验(Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in...
View Article